CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
For the period ended Jun 27, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 27, 2026 · Filed Aug 5, 2026
CRL$345.80-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Six Months Ended | ||
|---|---|---|
| June 27, 2026 | June 28, 2025 | |
| Cash flows relating to operating activities | ||
| Net income (loss) | $(15,562) | $78,571 |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 134,441 | 239,871 |
| Long-lived asset impairments | 26,279 | 31,203 |
| Stock-based compensation | 42,162 | 30,184 |
| Deferred income taxes | 12,077 | (41,030) |
| Write down of inventories | 3,165 | 11,067 |
| (Gains) losses and impairments on venture capital and strategic equity investments, net | (6,936) | 12,899 |
| Gain on sale of assets | (38,484) | — |
| Provision for credit losses | 1,124 | 2,191 |
| (Gain) loss on divestitures, net | 181,386 | (3,376) |
| Other, net | (12,595) | 2,266 |
| Changes in assets and liabilities: | ||
| Trade receivables and contract assets, net | (87,135) | (18,490) |
| Inventories | 43,747 | (13,953) |
| Accounts payable | 21,276 | 16,241 |
| Accrued compensation | (64,858) | 38,990 |
| Deferred revenue | 5,593 | 11,306 |
| Customer contract deposits | (4,543) | 568 |
| Other assets and liabilities, net | (20,335) | (22,208) |
| Net cash provided by operating activities | 220,802 | 376,300 |
| Cash flows relating to investing activities | ||
| Acquisition of businesses and assets, net of cash acquired | (467,254) | — |
| Capital expenditures | (87,013) | (94,622) |
| Purchases of investments and contributions to venture capital investments | (11,805) | (8,090) |
| Proceeds from sale of investments | 11,059 | 2,106 |
| Proceeds from sale of businesses and assets, net | 176,563 | 17,441 |
| Other, net | (1,298) | 347 |
| Net cash used in investing activities | (379,748) | (82,818) |
| Cash flows relating to financing activities | ||
| Proceeds from long-term debt and revolving credit facility | 1,265,258 | 963,363 |
| Payments on long-term debt, revolving credit facility, and finance lease obligations | (745,927) | (887,706) |
| Proceeds from exercises of stock options | 1,620 | 1 |
| Purchase of treasury stock | (323,881) | (360,484) |
| Payments of contingent consideration | (11,400) | (21,822) |
| Purchase of remaining equity interests of other redeemable noncontrolling interest | — | (19,140) |
| Other, net | (2,607) | (6,458) |
| Net cash provided by (used in) financing activities | 183,063 | (332,246) |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 467 | 17,934 |
| Net change in cash, cash equivalents, and restricted cash | 24,584 | (20,830) |
| Cash, cash equivalents, and restricted cash, beginning of period | 215,997 | 205,570 |
| Cash, cash equivalents, and restricted cash, end of period | $240,581 | $184,740 |
| See Notes to Unaudited Condensed Consolidated Financial Statements. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.